Methods of treating cancer by targeting tumor-associated macrophages
US-2024415921-A1 · Dec 19, 2024 · US
US11951187B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11951187-B2 |
| Application number | US-202117179948-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 19, 2021 |
| Priority date | Feb 19, 2020 |
| Publication date | Apr 9, 2024 |
| Grant date | Apr 9, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The disclosure provides NIR-II imaging probes and methods of using the NIR-II imaging probes for dynamic in vivo tracking of cells, such as stem cells, or other substances. NIR-II imaging probes can include a biocompatible NIR-II dye molecule coupled to an organic, biocompatible protein carrier complex, including a carrier protein coupled to a cell-penetrating peptide.
Opening claim text (preview).
The invention claimed is: 1. An NIR-II optical imaging probe comprising: a biocompatible NIR-II dye molecule coupled to an organic, biocompatible protein carrier complex, the protein carrier complex comprising a carrier protein coupled to a cell-penetrating peptide (CPP), wherein the probe emits detectable NIR-II fluorescence and wherein the molar ratio of the NIR-II dye molecule to carrier protein to CPP is from about 0.5-1.5 NIR-II dye molecule to 0.5-1.5 carrier protein to 0.5-1.5 CPP. 2. The NIR-II optical imaging probe of claim 1 , wherein the carrier protein comprises a serum albumin protein. 3. The NIR-II optical imaging probe of claim 2 , wherein the serum albumin protein is selected from human serum albumin (HSA) molecule and bovine serum albumin (BSA) molecule. 4. The NIR-II optical imaging probe of claim 1 , wherein the CPP comprises trans-activator of transcription (Tat) peptide of HIV, or a derivative or segment thereof retaining cell membrane penetrating functionality. 5. The NIR-II optical imaging probe of claim 4 , wherein the Tat peptide comprises a peptide sequence having at least 75% sequence identity with SEQ ID NO: 1. 6. The NIR-II optical imaging probe of claim 1 , wherein the biocompatible NIR-II dye molecule is selected from the group consisting of: CH-4T, CH1055, carboxyl NIR-II dye molecules, NIR-II cyanine dye molecules, and combinations thereof. 7. The NIR-II optical imaging probe of claim 6 , wherein the biocompatible NIR-II dye molecule is CH-4T. 8. The NIR-II optical imaging probe of claim 1 , wherein the carrier protein is coupled to the CPP through a carbodiimide-mediated coupling reaction. 9. The NIR-II optical imaging probe of claim 1 , wherein the molar ratio of the NIR-II dye molecule to carrier protein to CPP is about 1 NIR-II dye molecule to 1 carrier protein to 1 CPP. 10. A cell including at least one NIR-II optical imaging probe of claim 1 . 11. The cell of claim 10 , wherein the cell is selected from the group consisting of: a stem cell, a pluripotent cell, an immune cell, a donor cell, and a cancer cell. 12. The cell of claim 10 , wherein the cell is a human stem cell. 13. A pharmaceutically acceptable imaging composition comprising: a plurality of NIR-II optical imaging probes of claim 1 or a plurality of target cells, wherein at least a portion of the target cells each include one or more of the NIR-II optical imaging probes of claim 1 ; and a pharmaceutically acceptable carrier. 14. The pharmaceutically acceptable imaging composition of claim 13 , wherein the composition comprises a plurality of target cells, wherein at least a portion of the target cells each include one or more of the NIR-II optical imaging probes of claim 1 and wherein the cells are selected from the group consisting of: stem cells, immune cells, and donor cells. 15. An imaging kit comprising: the pharmaceutically acceptable imaging composition of claim 13 , and instructions for administration of the pharmaceutically acceptable imaging composition to a patient and imaging of the patient.
Peptides, proteins, polyamino acids · CPC title
the fluorescent group being a small organic molecule · CPC title
Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.